Check 35,000+ stocks against 26 valuation models and 37 quality factors

Shalby Limited (SHALBY) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Shalby Limited ₹63.00, price ₹134, upside -52.8%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · IN · ISIN INE597J01018

SL Broad data Sep 24, 2026

Shalby Limited

SHALBY · NSE

Weakest SetupStrongly overvalued and low quality.

!Fair value ₹63.00 · Strongly overvalued (−52.8%)

!Quality 31/100

!Expensive Growth (revenue 5y +21.5 %/yr)

!Thin margins · 3.3% net margin (TTM)

!Low debt · negative free cash flow

!Trails peers (2/13)

!Narrow moat 24/100

!Weak on past: 14 out of 100

!Weak on dividend: 14 out of 100

26 models, one by oneBear ₹44.43 to bull ₹92.10 Growth analysisrevenue history, year by year Quality 31/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Shalby Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ₹94.30 – ₹321.68 · fair‑value band ₹44.43 – ₹92.10 · the ₹133.55 price screens above the ₹63.00 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Shalby in your weekly email

Every Wednesday you see whether Shalby is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments.

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.

Stock analysis

Shalby Limited (SHALBY) currently trades at ₹133.55, while our model-based Fair Value estimate is ₹63.00, 52.8% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹77.18 per share, and 1 of the 16 models we run sit above the ₹133.55 price.

Bear case: the Dividend Discount group reads lowest at ₹13.37, and 15 of the 16 models stay below the price. Evidence for this calculation is high.

Scenario range: ₹44.43 (bear) to ₹92.10 (bull), the price of ₹133.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Shalby Limited reported revenue of ₹11.4B in FY2026 versus ₹7.0B in FY2022, a compound +13.0%/yr. Reported net income was ₹374M in FY2026, compounding −8.8%/yr from FY2022.

Key figures

Market cap ₹18.6B (≈ $194M) · P/E ratio 41.2 · P/S ratio 1.35 · EPS (TTM) ₹3.24 · Dividend yield 0.7% · Net margin 3.3% · Return on equity 3.5% · Return on assets (EBIT) 7.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −53%, SHALBY screens richer than that median.

Fair Value models

Bear ₹44.43 Fair Value ₹63.00 Bull ₹92.10

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.65 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

Residual Income ₹62.25 ₹58.97 ₹58.77 76

EPV ₹19.47 ₹23.27 ₹26.35 74

ROIC Compounder ₹19.47 ₹23.27 ₹26.35 72

All 16 models by family

Earnings-Based

Graham-Dodd ₹23.70 ₹130.49 ₹181.07 63

Lynch FV ₹36.34 ₹51.92 ₹67.50 61

PEG = 1.0 ₹36.34 ₹51.92 ₹67.50 57

EPV ₹19.47 ₹23.27 ₹26.35 74

Dividend Discount

Gordon GGM ₹8.41 ₹14.09 ₹18.29 68

DDM Multi-Stage ₹8.41 ₹13.37 ₹15.16 67

Multiples

P/E Multiple ₹57.50 ₹76.66 ₹95.83 63

P/S Multiple ₹44.43 ₹59.24 ₹74.05 58

P/B Multiple ₹44.43 ₹59.24 ₹74.05 55

EV/EBIT ₹75.08 ₹104.17 ₹133.26 66

EV/EBITDA ₹128.16 ₹174.95 ₹221.74 67

EV/Revenue ₹50.09 ₹76.79 ₹103.48 53

Asset-Based

NCAV (Graham) ₹46.84 ₹62.77 ₹93.69 54

Economic Profit

Residual Income ₹62.25 ₹58.97 ₹58.77 76

ROIC Compounder ₹19.47 ₹23.27 ₹26.35 72

Growth Earnings

Growth-Adj P/E ₹54.03 ₹77.18 ₹100.34 67

Open the full fair value analysis →

Notify me when SHALBY reaches fair value

Put SHALBY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 31/100

Of which business quality 32 · Market factors (momentum, volatility) 31

Profitability 28

Margins and returns on capital today

Quality Growth 43

Are margins and returns improving?

Cashflow 3

Earnings quality: real cash, not paper profit

Fin. Strength 49

Balance sheet, leverage, solvency risk

Investment 54

Disciplined investing over empire-building

Low Volatility 77

Calm price path (market factor)

Momentum 17

Price trend over the last 3–12 months (market factor)

52W Momentum 2

Distance to the 52-week high (market factor)

Net Issuance 29

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+5.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+12.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+21.5%

Start year 2021 (pandemic). Over 10 years: +14.7% a year

Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.2%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+4.9%

Earnings growth per share plus dividend.

Earnings per share, growth per year+4.2%

Dividend (yield on the price)0.7%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.8% vs −0.7%, slowing

Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 6%

Start year 2021 (pandemic)

SHALBY screens overvalued: fair value 53% below the price. Compare with HCA Healthcare, Inc →

Compare Shalby Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks

Beats the industry median on 2/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 31 · Bottom 25%

Fair Value upside −81.8% · Bottom 25%

Profitability

Return on equity (TTM) 3.5% · Below median

Return on assets 2.6% · Below median

Net margin (TTM) 3.3% · Below median

Operating margin (TTM) 3.8% · Bottom 25%

Growth and dividend

Revenue growth 8.5% · Above median

Dividend yield (TTM) 0.7% · Bottom 25%

Balance sheet

Debt / equity 0.15× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 41.2× · Priciest 25%

P/B 1.85× · Pricier than median

P/S (TTM) 1.63× · Pricier than median

EV/EBITDA 14.0× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 34

FUTURE (revenue growth)43 · sector 26

PAST (return on equity)14 · sector 31

HEALTH (low debt)92 · sector 90

DIVIDEND (yield)14 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc HCA	$431.63	$597.97	+39%
Fresenius SE FRE	€43.64	€34.49	−21%
Dr. Sulaiman Al Habib Medical Services Group 4013	225.00 SAR	109.45 SAR	−51%
Tenet Healthcare Corporation THC	$257.93	$274.35	+6%
IHH Healthcare Berhad, an investment holding company, 5225	8.03 MYR	4.87 MYR	−39%
Apollo Hospitals Enterprise Limited APOLLOHOSP	₹8,889	₹2,908	−67%
Encompass Health Corporation EHC	$123.47	$94.47	−23%
Fresenius Medical Care AG FMS	$22.27	$45.84	+106%
DaVita Inc DVA	$178.07	$215.81	+21%
Aier Eye Hospital Group 300015	¥7.91	¥10.86	+37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shalby Limited · Fair Value
₹63.00 −53%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/SHALBY" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Shalby Limited · Fair Value</span><br><b style="font-size:20px">₹63.00</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−53%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Shalby Limited Fair Value". https://www.fairvalue-calculator.com/stock/SHALBY

Frequently asked questions

Is Shalby Limited (SHALBY) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ₹63.00 versus a price of ₹133.55, about −53% upside (overvalued).

What is the fair value of SHALBY?

Our model-based fair value for Shalby Limited is ₹63.00 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹133.55.

What is the quality score of SHALBY?

Shalby Limited has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Shalby Limited (SHALBY)?

Our model-based price target is the fair value of ₹63.00 (as of Sep 24, 2026) from 16 valuation models. Cautious scenario ₹44.43, optimistic scenario ₹92.10. It is a calculation from audited fundamentals, not an analyst target.

What is the Shalby Limited stock forecast for 2026?

Our models put fair value at ₹63.00, about −53% upside versus a price of ₹133.55 (overvalued). Cautious scenario ₹44.43, optimistic scenario ₹92.10. The calculation is refreshed regularly with new filings.

What is the revenue of Shalby Limited (SHALBY)?

Shalby Limited reported trailing-twelve-month revenue of about ₹11.4B (latest available figure, as of Sep 24, 2026).

Does Shalby Limited pay a dividend?

Shalby Limited currently shows a dividend yield of about 0.70% relative to its recent price (as of Sep 24, 2026).

What is the intrinsic value of Shalby Limited (SHALBY)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shalby Limited it is ₹63.00 per share (as of Sep 24, 2026), against a price of ₹133.55. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).

Is Shalby Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, SHALBY trades above its calculated fair value: price ₹133.55, fair value ₹63.00, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of SHALBY?

No. The price is what the market pays today (₹133.55); the fair value is what the company's own numbers justify (₹63.00). For Shalby Limited the two are ₹70.55 per share apart. That gap is exactly why we show both numbers side by side.

How much is Shalby Limited worth?

The market values Shalby Limited at about ₹18.6B (market capitalisation, as of Sep 24, 2026). Per share that is ₹133.55; our models calculate a fair value of ₹63.00 per share.

What do the bullish and bearish scenarios say about SHALBY?

Our models span a range for Shalby Limited: cautious scenario ₹44.43, base ₹63.00, optimistic ₹92.10 per share (as of Sep 24, 2026, price ₹133.55). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of SHALBY?

Shalby Limited trades at a price-to-earnings ratio of 41.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹63.00 is built from several models across several years. Other multiples: P/B 1.9, P/S 1.6, EV/EBITDA 14.0.

How solid is the balance sheet of Shalby Limited (SHALBY)?

Balance-sheet figures for Shalby Limited (as of Sep 24, 2026): return on equity 3.5%, debt of 0.15 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.

How far is SHALBY from its 52-week high?

Shalby Limited trades at ₹133.55, about 50% below its 52-week high of ₹266.25 and 5% above the low of ₹126.80 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹63.00 is for.

Which stocks are comparable to Shalby Limited?

From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Shalby Limited stock attractive at the current price?

The data as of Sep 24, 2026: price ₹133.55, calculated fair value ₹63.00 (−53%), Quality Score 31/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of SHALBY calculated?

We run Shalby Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹63.00, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Shalby Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Shalby Limited (SHALBY)?

The closing price on Oct 1, 2026 was ₹133.55. Our model-based fair value is ₹63.00, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Shalby Limited right now?

The price sits above even our optimistic bull case (₹92.10). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (₹44.43 to ₹92.10) leaves room in how you read the outcome.

Where does the earnings growth of Shalby Limited (SHALBY) come from?

Earnings per share at Shalby Limited grew −0.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +14.8 %, EBIT margin −4.1 %, tax rate −6.5 %, residual (interest, one-offs) −2.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Shalby Limited

How large is the market capitalisation of Shalby Limited (SHALBY)?

The market capitalisation of Shalby Limited is ₹18.6B (≈ $194M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Shalby Limited (SHALBY)?

The price-to-sales ratio of Shalby Limited is 1.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Shalby Limited (SHALBY)?

Earnings per share at Shalby Limited are ₹3.24 (price ÷ EPS = P/E 41.2). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Shalby Limited (SHALBY)?

The dividend yield of Shalby Limited is 0.7% (payout 28.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Shalby Limited (SHALBY)?

The net margin of Shalby Limited is 3.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Shalby Limited (SHALBY)?

The return on equity (ROE) of Shalby Limited is 3.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Shalby Limited (SHALBY)?

On an EBIT basis the return on assets of Shalby Limited is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Shalby Limited (SHALBY)?

The operating margin of Shalby Limited is 3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Shalby Limited (SHALBY)?

Revenue at Shalby Limited is growing +8.5% versus a year earlier (3y avg +12.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Shalby Limited (SHALBY)?

Earnings per share at Shalby Limited are growing −48.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Shalby Limited (SHALBY) generate?

The free cash flow of Shalby Limited is −₹1.8B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Shalby Limited (SHALBY) carry?

The net debt of Shalby Limited is ₹5.7B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Shalby Limited in the live analysis

One click puts Shalby Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.